Skip to content

Community Trial of Newborn Vitamin A Supplementation to Reduce Infant Mortality in Rural Bangladesh

A Randomized Community Trial of Newborn Vitamin A Supplementation to Reduce Infant Mortality in Rural Bangladesh

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00128557
Enrollment
15937
Registered
2005-08-10
Start date
2004-01-31
Completion date
2006-12-31
Last updated
2022-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mortality Through Six Months of Age, Vitamin A Deficiency

Keywords

Vitamin A, Newborn health, Infant Mortality, Supplementation, Micronutrients, Bangladesh

Brief summary

The purpose of this trial is determine whether a 50,000 IU oral dose of vitamin A delivered to newborn infants within the first days of life, reduces six-month infant mortality by at least 15%. The trial will also evaluate whether the survival impact of newborn vitamin A dosing is modified by concurrent weekly, routine maternal vitamin A or beta-carotene supplementation during pregnancy through three months postpartum, gestational age and birth size.

Detailed description

This is a randomized, double-masked, placebo-controlled, community trial of newborn vitamin A supplementation on mortality in the first six months of life. The trial is being implemented in 596 sectors (i.e. villages and/or smaller groupings), in two thanas comprising a population of \ 580,000 in rural northern Bangladesh (Gaibandha/Rangpur area) and is nested within the JiVitA-1 maternal supplementation study. Women residing in the study area are already under 5-weekly pregnancy surveillance conducted by village-based field staff as part of the maternal supplementation trial. During their third trimester of pregnancy, women are visited by a study supervisor who explains the purpose and procedures of the study. After obtaining informed consent, women are interviewed for possible risk factors in the third trimester of pregnancy, including a 30-day history of morbidity, a 7-day dietary and alcohol intake and tobacco use questionnaire, a 7-day household chores questionnaire, and maternal anthropometry (mid upper arm circumference measurement). Upon birth, household members contact the village-based field staff who immediately administers the vitamin A or placebo to the infant, according to sector assignment. After supplementation, newborns are measured for weight, length and mid-upper arm, head and chest circumference, and then followed weekly for vital status for three months, and again at six months of age. A child death initiates the process of death verification and cause of death determination.

Interventions

DIETARY_SUPPLEMENTvitamin A supplementation (15,000 ug retinol equivalents or 50,000 IU)

Single dose of 15,000 ug retinol equivalents at or near birth vs a placebo

Sponsors

United States Agency for International Development (USAID)
CollaboratorFED
Johns Hopkins University
CollaboratorOTHER
Bill and Melinda Gates Foundation
CollaboratorOTHER
Canadian International Development Agency
CollaboratorOTHER_GOV
Access Business Group
CollaboratorINDUSTRY
Johns Hopkins Bloomberg School of Public Health
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
1 Minutes to 30 Days
Healthy volunteers
Yes

Inclusion criteria

Infants born to women enrolled in a maternal supplementation trial, alive and less than 30 days of age during a newborn dosing visit

Exclusion criteria

Infants who died before the dose could be administered or infants older than 30 days at the time of dosing

Design outcomes

Primary

MeasureTime frame
24-week infant mortality rate

Countries

Bangladesh

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026